Singapore AI Healthtech Holmusk Raises $45M Series C for APAC Mental Health Data Platform

## Holmusk $45M Series C: AI for the APAC Mental Health Treatment Gap

Holmusk, a Singapore-headquartered digital health company, has raised $45M in a Series C funding round to expand its AI-powered mental health data platform across APAC. The round represents one of the largest healthtech raises in Singapore in 2026 and signals growing investor confidence in APAC-origin healthcare AI companies.

### What Holmusk Does

Holmusk operates at the intersection of mental health care delivery and data science. The company's flagship product is NeuroBlu — a real-world evidence (RWE) platform that aggregates de-identified psychiatric patient data from health systems and uses AI and statistical analysis to generate insights for:

- **Pharmaceutical companies**: identifying patient populations for clinical trials, understanding treatment patterns and outcomes, and generating regulatory-grade real-world evidence - **Health systems**: understanding population-level mental health trends, optimising care pathways, and benchmarking outcomes against comparable populations - **Researchers**: accessing structured real-world mental health data for epidemiological and health economics research

### The APAC Mental Health Opportunity

The APAC mental health market has several characteristics that make Holmusk's data platform particularly relevant:

**Treatment gap**: Across APAC, the proportion of people with mental health conditions who receive treatment ranges from 5% (Indonesia, Vietnam) to 30% (Australia, Singapore). Data-driven insights are needed to understand and close this gap.

**Underdeveloped data infrastructure**: Mental health data in APAC is highly fragmented and inconsistently structured. Countries like Japan and Korea have significant psychiatric care capacity but minimal data standardisation — creating an opportunity for platforms that can aggregate and harmonise this data.

**Regulatory tailwinds**: Singapore, Australia, and Japan are developing national mental health data strategies that create demand for data platforms that can support population-level analysis.

### AIMenta Assessment

Holmusk represents the emerging category of APAC-origin, domain-specific AI companies that are building durable competitive positions by combining deep local market knowledge with AI-native data products. The mental health domain is particularly attractive because data is genuinely scarce, domain expertise is critical, and regulatory requirements create a moat against generalist AI competitors.

For APAC health systems and policymakers interested in mental health analytics: Holmusk's NeuroBlu platform is worth evaluating for population-level mental health strategy and outcome benchmarking.